Clearmind Medicine Seeks Israeli Patent For Novel Neuroplastogen Treatment Offering Depression Relief Without Hallucinogenic Effects

Clearmind Medicine Inc., a clinical-stage biotechnology company developing psychedelic-derived therapies for difficult and under-treated health conditions, has announced the submission of a new patent application in Israel. The filing covers a combination therapy that pairs 5-methoxy-2-aminoindane (MEAI) with N-Acylethanolamines, including Palmitoylethanolamide (PEA), specifically for the treatment of depression.

This patent application is the result of Clearmind’s ongoing collaboration with Neurothera Labs Inc., a subsidiary of SciSparc Ltd. Together, the companies are working on developing therapies that use MEAI and PEA to address major depressive disorder. Depression continues to affect more than 280 million people worldwide, according to the World Health Organization, and remains one of the leading causes of disability. Despite its widespread impact, there has been limited progress in bringing new and innovative treatment options to patients.

In the announcement, Clearmind’s CEO, Adi Zuloff-Shani, PhD, noted that the patent filing represents another significant milestone for the company. She explained that depression remains a global challenge, and the lack of meaningful treatment innovation over decades highlights the need for new scientific approaches. She added that the collaboration with Neurothera continues to produce encouraging therapeutic possibilities, and this latest filing further strengthens the company’s intellectual property as it works to advance MEAI-based treatments into clinical development.

The new patent expands Clearmind’s already growing intellectual property portfolio. The company has now filed 13 patents related to its work with Neurothera, covering several therapeutic areas. These include the use of MEAI and N-Acylethanolamines combinations for managing alcohol use disorder, cocaine addiction, obesity, weight loss, and depression. Early preclinical data suggest that MEAI may help reduce addictive behaviors without interfering with normal reward pathways, offering potential benefits in both addiction and mental health treatment.